Seeking Alpha

Mayo Clinic study boosts Geron

  • Shares of Geron (GERN) are up 9% in premarket trading.
  • Behind the move looks to be an article outlining a Mayo Clinic study which says imetelstat "has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis."
  • The study's lead author calls the results "early but promising."
  • Amusingly, the article appears to have been posted ahead of its scheduled release from embargo.
  • Full article is here
Comments (1)
  • carlbatt
    , contributor
    Comment (1) | Send Message
     
    This isn't an article but a press release from the Mayo Clinic trying to promote attention to the presentation. It is standard operating protocol for most institutions who are attempting to draw attention to their work, from donors, alums or others.
    6 Dec 2013, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector